Pharmaceuticals, Life Sciences, and Healthcare

Businesses increasingly realize that significant growth opportunities are unlikely to come from incremental change.

Learning what, when and where it's needed.

The Office of the Governor of the State of California and representatives from Life Sciences clusters produced strategic action plans.

Scenario Thinking for Business Executives and Corporate Boards.

Health care is on a collision course with patient needs and economic reality.

The antithesis of a traditional business model, biotechnology company Maxygen is the poster child for a new “biomolecular” way of organizing enterprise. Monitor’s Chris Meyer and Joan Chu analyze Maxygen’s paradigm – and question its sustainability – in their The Journal of Life Sciences article.

Today’s emphasis on innovation in the biopharmaceutical industry is driven by the resistance of payers to pay premium prices for medicines.

Successfully pricing products and services is one of the biggest challenges sales and marketing professionals face.

The report reviews the current status of the Shanghai/Pudong Life Sciences Cluster and identifies those areas where it has potential to develop a sustainable competitive advantage, including the specific actions that should be taken to realize the vision.

Remote Health Services (RHS) allow the patient to be treated wherever he/she is or chooses to be. Instead of having to take a trip to a doctor's office or hospital to be diagnosed and treated by trained  professionals, they come to him/her, virtually, thanks to the advances in information technology and telecommunications.

Telemedicine is poised to create a significant impact on the way patients are diagnosed, monitored and treated. It is also going to play an important role in keeping the population healthy in the future.

By 2010, customized medicare of some meaningful kind, will in all likelihood, become a reality.

Today’s ailing economy has corporations and consumers alike demanding higher value for lower cost, and pharmaceuticals are no exception. In a recent Pharmaceutical Executive article, Monitor Partner Thomas Nagle offers three pricing models designed to optimize revenue without compromising patient care.